52.8 million global deaths caused mainly by communicable infectious diseases and concomitant antimicrobial resistance (in 2010)
5 billion cases of oral infections rank them as the most prevalent chronic diseases worldwide (in 2014)

Yet, the detection of the correct pathogen agent of such diseases is still a relatively time-consuming process, taking up to several days and requiring central diagnostic laboratories.

Respiratory tract infections and oral infections are also accompanied by high socioeconomic costs (hospitalization, absence from work, burden on healthcare costs and insurance systems).

In response to this global health and economic burden, the DIAGORAS project intends to conceive and develop a diagnostic device that will identify – within 1 hour – a wide range of viruses and bacteria responsible for respiratory and oral infections, including major viral and bacterial pathogens associated with global morbidity and mortality.

Where does DIAGORAS come from?origins icon

Diagnostic Workflow

How will it be useful for general practicioners and emergency rooms?

The device will allow to rapidly detect – by measuring the bacterial or viral DNA (qPCR, RT-qPCR) – the most common upper and lower respiratory infections, such as pneumonia, pharyngitis, rhinitis, sinusitis, chronic obstructive pulmonary disease, tonsillitis, otitis media, etc.

It will also be able to identify antibiotic resistance-genes, since antibiotic resistance is a global issue that increases with the overuse of antibiotics.

How will it be useful for dentists?

Since periodontitis and caries are the most prevalent chronic diseases worldwide, the device will offer to rapidly identify – by measuring the bacterial DNA (qPCR) and using human protein biomarkers – the bacteria causing these infections.

The device will faster the diagnostic workflow of oral infections and will act as a preventive diagnostic tool, avoiding the need for further costly treatment.

An interdisciplinary project

The project involves partners from different domain expertise that work together to:

  • design microfluidic structures and their interface so as to produce a fully-automated sample-to-answer analysis, with integrated assays and biochemical components
  • develop nucleic acid assays, in PCR and qualitative microarray configuration, first in tube, and then transfer of protocols to disc

All the process will go through validation and quality control to insure a high quality at all level of the project.
Validation will also insure integration towards clinical diagnosis.